Schizopsychotic symptom-profiles and biomarkers: Beacons in diagnostic labyrinths

Neurotoxicity Research

Volumn 14, Issue 2-3, 2008, Pages 79-96

  Palomo, Tomas ^a   Kostrzewa, Richard M ^b   Beninger, Richard J ^c   Archer, Trevor ^d,e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b East Tennessee State University   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Cannabis use; Chromosomal abnormality; Functional dysconnectivity; Neurocognition; Premorbidity; Regional vulnerability; Schizopsychosis; Stereotypy; Super sensitivity

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIS; CATECHOL METHYLTRANSFERASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DYSBINDIN; GLUTAMATE RECEPTOR 4; HALOPERIDOL; NEU DIFFERENTIATION FACTOR; NEUROTRANSMITTER; OLANZAPINE; OXIDOPAMINE; PHOSPHODIESTERASE IV; RISPERIDONE; SEROTONIN; TRANSCRIPTION FACTOR; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; BRAIN DYSFUNCTION; BRAIN REGION; CANNABIS ADDICTION; CHROMOSOME 22; CHROMOSOME ABERRATION; CHROMOSOME DELETION; DISEASE ASSOCIATION; HEREDITY; HUMAN; MENTAL DEFICIENCY; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; ANIMAL; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; NERVE TRACT; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SYNAPTIC TRANSMISSION;

CANNABIS;

ANIMALS; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; COGNITION DISORDERS; HUMANS; NEURAL PATHWAYS; NEUROGENESIS; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 63249125802     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033800     Document Type: Article

References (275)

1. Abel KM, S Jolley, DR Hemsley and MA Geyer (2004) The influence of stereotypy traits on prepulse inhibition in young healthy controls. J. Psychopharmacol. 18, 181-188.
2. 1 receptors and the pathology of schizophrenia. Neuroscientist 9, 404-416.
3. Abi-Gargham A, R Gil, J Krystal, R Baldwin, J Seibyl, M Bowers, C van Dyck, D Charney, R Innis and M Laruelle (1998) Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am. J. Psychiatry 155, 761-767.
4. 2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA 97, 8104-8109.
5. 1 receptors and working memory in schizophrenia. J. Neurosci. 22, 3708-3719.
6. Abi-Dargham A, L Kegeles, M Slifstein and M Laruelle (2008) Relationships between dopamine function and clinical dimensions,. In: Beyond Neuropsychiatric Diagnostics: Symptoms Not Disorders (Palomo T, RJ Beninger, RM Kostrzewa and T Archer, Eds.) (Fundación Cerebro y Mente:MAdrid, Spain) (in press).
7. Abou Jamra R, C Schmael, S Cichon, M Rietschel, J Schumacher and MM Nothen (2006) The G72/G30 gene locus in psychiatric disorders: A challenge to diagnostic boundaries? Schizophr. Bull. 32, 599-608.
8. Addington J and D Addington (1999) Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 25, 173-182.
9. Addington J, H Saeedi and D Addington (2005) The course of cognitive functioning in first episode psychosis: Changes over time and impact on outcome. Schizophr. Res. 78, 35-43.
10. Allardyce J, J Boydell, J van Os, G Morrison, D Castle and RM Murray (2001) A comparison of the incidence of schizophrenia in rural Dumfries and Galloway and urban Camberwell. Br. J. Psychiatry 179, 335-339.
11. Andreasen NC (1997) The role of the thalamus in schizophrenia. Can. J. Psychiatry 42, 27-33.
12. Andreasen NC, P Nopoulos, DS O'Leary, DD Miller, T Wassink and M Flaum (1999) Defining the phenotype of schizophrenia: Cognitive dysmetria and its neural mechanisms. Biol. Psychiatry 46, 908-920.
13. Andreasson S, P Allebeck, A Engström and U Rydberg (1987) Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet 2, 1483-1486.
14. Archer T and A Fredriksson (2007) Behavioural supersensitivity following 6-hydroxydopamine: Attenuation by MK-801. Neurotox. Res. 12, 113-124.
15. Archer T, A Fredriksson, E Sundström, J Luthman, T Lewander, U Söderberg and G Jonsson (1988) Prenatal methylazoxymethanol treatment potentiates d-amphetamine- and methylphenidate-induced motor activity in male and female rats. Pharmacol. Toxicol. 63, 233-239.
16. Arendt M, R Rosenberg, L Foldager, G Perto and P Munk-Jorgensen (2005) Cannabis induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. Br. J. Psychiatry 20, 349-353.
17. Arseneault L, M Cannon, R Poulton, R Murray, A Caspi and TE Moffit (2002) Cannabis use in adolescent and risk for adult psychosis: longitudinal prospective study. Br. Med. J. 325 (7374), 1212-1213.
18. 1β-adrenergic receptors: Relationship between functional and nonfunctional dopamine release. J. Neurosci. 22, 9150-9154.
19. 1β-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur. J. Neurosci. 20, 3073-3084.
20. Baare WF, HE Hulshoff Pol, R Hijman, WP Mali, MA Viergever and RS Kahn (1999) Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol. Psychiatry 45, 1597-1605.
21. Barch DM, CS Carter, TS Braver, FW Sabb, A MacDonald, DC Noll and JD Cohen (2001) Selective deficits in prefrontal cortex function in medication-naïve patients with schizophrenia. Arch. Gen. Psychiatry 58, 280-288.
22. Bartok E, R Berecz, T Glaub and I Degrell (2005) Cognitive functions in prepsychotic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 621-625.
23. Bassett AS and EWC Chow (1999) 22q11 Deletion syndrome: A genetic subtype of schizophrenia. Biol. Psychiatry 46, 882-891.
24. Baumer H (1954) On the nature of the thalamus in schizophrenia. J. Hirnforsch. 1, 157-172.
25. Bearden CE, MF Woodim, PP Wang, E Moss, D McDonald-McGinn, E Zackai, B Emannuel and TD Cannon (2001) The neurocognitive phenotype of the 22q1 1.2 deletion syndrome: Selective deficit in visual-spatial memory. J. Clin. Exp. Neuropsychol. 23, 447-464.
26. Bechdorf A, S Ruhrmann, M Wagner, KU Kuhn, R Bottlender et al., (2005) Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. Br. J. Psychiatry 48, 45-48.
27. Bell MD and G Bryson (2001) Work rehabilitation in schizophrenia: Does cognitive impairment limit improvement? Schizophr. Bull. 27, 269-279.
28. Bilder RM, RS Goldman, D Robinson, G Reiter, L Bell, JA Bates et al. (2000) Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am. J. Psychiatry 157, 549-559.
29. Blackwood DH, A Fordyce, MT Walker, DM St Clair, DJ Porteous and WJ Muir (2001) Schizophrenia and affective disorders - cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: Clinical and P300 findings in a family. Am. J. Hum. Genet. 69, 428-433.
30. Blackwood DH, T Thiagarajah, MP Malloy, BS Pickard and WJ Muir (2008) Chromosome abnormalities, mental retardation and the search for genes in bipolar disorder and schizophrenia. Neurotox. Res. 14 (113-120).
31. Bohm D, K Hoffman, F Laccone, B Wilken, P Dechent, J Frahm, I Bartels and SK Bohlander (2006) Association of Jacobsen syndrome and bipolar affective disorder in a patirnt with a de novo 11q terminal deletion. Am. J. Med. Genet. A 140, 378-382.
32. Botto LD, K May, PM Fernhoff, A Correa, K Coleman, SA Rasmussen, RK Merritt, LA O'Leary, LY Wong et al. (2003) A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatr. 112, 101-107.
33. Boydell J, J van Os, M Lambri, D Castle, J Allardyce, RG McCreadie and RM Murray (2003) Doubling in incidence of schizophrenia in South-East London between 1965 and 1997. Br. J. Psychiatry 182, 45-49.
34. Boydell J, J van Os, A Caspi, N Kennedy, E Giouroukou, P Fearon, M Farrell and RM Murray (2006) Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol. Med. 36, 1441-1446.
35. Braver TS, JD Cohen, LE Nyström, J Jonides, EE Smith and DC Noll (1997) A parametric study of prefrontal cortex involvement in human working memory. NeuroImage 5, 49-62.
36. Brazo P, P Delamillieure, R Morello, I Halbecq, RM Marié and S Dollfus (2005) Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms. Psychiatry Res. 133, 45-55.
37. Brébion G, X Amador, MJ Smith and JM Gorman (1998) Memory impairment and schizophrenia: The role of processing speed. Schizophr. Res. 30, 31-39.
38. Breese GR, AA Baumeister, TC Napier, GD Frye and RA Mueller (1985) Evidence that D-1 dopamine receptors contribute to the supersensitive behavioural responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235, 287-295.
39. Breier A, JL Schreiber, J Dyer and D Pickar (1991) National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arch. Gen. Psychiatry 48, 239-246.
40. Brewer WJ, SM Francey, SJ Wood, HJ Jackson, C Pantelis, LJ Phillips et al. (2005) Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry 162, 71-78.
41. Brewer WJ, SJ Wood, LJ Phillips, SM Francey, C Pantelis, AR Yung et al. (2006) Generalized and specific cognitive performance in clinical high-risk cohorts: A review highlighting potential vulnerability markers for psychosis. Schizophr. Bull. 32, 538-555.
42. Brockhaus-Dumke A, I Tendolkar, R Pukrop, F Schultze-Lutter, J KlosterKotter and S Ruhrmann (2005) Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr. Res. 73, 297-310.
43. Brus R, RM Kostrzewa, KW Perry and RW Fuller (1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J. Pharmacol. Exp. Ther. 268, 231-237.
44. Bunney WE and BG Bunney (2000) Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res. Brain Res. Rev. 31, 138-146.
45. Cadenhead KS, W Perry, K Shafer and DL Braff (1999) Cognitive functions in schizotypical personality disordered subjects. Schizophr. Res. 37, 123-132.
46. Cahn W, HE Pol, M Bongers, HG Schmack, RC Mandl, NE Van Haren et al. (2002) Brain morphology in antipsychoticnaive schizophrenia: A study of multiple brain structures. Br. J. Psychiatry 43, 66-72.
47. Callicott JH, A Bertolino, VS Mattay, FJ Langheim, J Duyn, R Coppola, TE Goldberg and DR Weinberger (2000) Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 10, 1078-1092.
48. Caluseriu O, G Mirza, J Ragoussis, EW Chow, D MacCrimmon and AS Bassett (2006) Schizophrenia in an adult with 6p25 deletion syndrome. Am. J. Med. Genet. A 140, 1208-1213.
49. Campbell LE, E Daly, F Toal, A Stevens, R Azuma, M Catani, V Ng, T van Amelsvoort, X Chitnis, W Cutter, DG Murphy and KC Murphy (2006) Brain and behaviour in children with 22q11.2 deletion syndrome: A volumetric and voxel-based morphometry MRI study. Brain 129, 1218-1228.
50. Cannon TD, B Cornblatt and P McGorry (2007) Introduction: The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr. Bull. 31, 661-664.
51. Carlson C, H Sirotkin, R Pandita, R Goldberg, J McKie, R Wadey, SR Patanjali, SM Weissman, K Antane-Yeboa et al. (1997) Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients. Am. J. Hum. Genet. 61, 620-629.
52. Carlson S, S Martinkauppi, P Rama, E Salli, A Korvenoja and HJ Aronen (1998) Distribution of cortical activation during visuospatial n-back tasks as revealed by functional magnetic resonance imaging. Cereb. Cortex 8, 743-752.
53. Carlsson A, N Waters, S Waters and ML Carlsson (2000) Network interactions in schizophrenia -therapeutic implications. Brain Res. Rev. 31, 342-349.
54. Caspi A, A Reichenberg, M Weiser, J Rabinowitz, Z Kaplan, H Knobler, N Davidson-Sagi and M Davidson (2003) Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr. Res. 65, 87-94.
55. Caspi A, ET Moffitt, M Cannon, J McClay, R Murray, HL Harrington, A Taylor, L Arseneault, B Williams, A Braithwaite, R Poulton and IW Craig (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene x environment interaction. Biol. Psychiatry 57, 1117-1127.
56. Castner SA and GV Williams (2007) Tuning the engine of cognition: A focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn. 63, 94-122.
57. Censits DM, JD Ragland, RC Gur and RE Gur (1997) Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: A longitudinal study. Schizophr. Res. 24, 289-298.
58. Chavarria-Siles I, J Contreras-Rojas, E Hare, C Walss-Bass, P Quezada, A Dassori, S Contreras, R Medina, M Ramirez, R Salazar, H Raventos and MA Escamilla (2008) Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147, 279-284.
59. Conkin HM, CE Curtis, J Katsanis and WG Iacono (2000) Verbal working memory impairment in schizophrenia patients and their first-degree relatives: Evidence from the digit span task. Am. J. Psychiatry 157, 275-277.
60. Corcoran C, D Malaspina and L Hercher (2005) Prodromal interventions for schizophrenia vulnerability: The risks of being "at risk". Schizophr. Res. 73, 173-184.
61. Cordes D, VM Haughton, K Arfanakis, JD Carew, PA Turski, CH Moritz, MA Quigley and ME Meyerand (2001) Frequencies contributing to functional connectivity in the cerebral cortex in "resting-state" data. AJNR. Am. J. Neuroradiol. 22, 1326-1333.
62. Cornblatt B and M Obuchowski (1997) Update of high-risk research: 1987-1997. Int. Rev. Psychiatry 9, 437-447.
63. Cornblatt B, T Lencz and M Obuchowski (2002) The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr. Res. 54, 177-186.
64. Craddock N, MC O'Donovan and MJ Owen (2007) Phenotypic and genetic complexity of psychosis. Invited commentary on schizophrenia: A common disease caused by multiple rare alleles. Br. J. Psychiatry 190, 200-203.
65. Craig TJ, EJ Bromet, S Fennig, M Tanenberg-Karant, J Lavelle and N Galambos (2003) Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am. J. Psychiatry 157, 60-66.
66. Crespo-Facorro B, C Paradiso, NC Andreasen, DS O'Leary, GL Watkins, LL Boles Ponto et al. (1999) Recalling word lists reveals "cognitive dysmetris" in schizophrenia: A positron emission tomography study. Am. J. Psychiatry 156, 386-392.
67. Crespo-Facorro B, R Roiz-Santianez, JM Pelayo-Teran, JM Rodriguez-Sanchez, R Perez-Iglesias, C Gonzalez-Blanch, D Tordesillas-Gutierrez, A Gonzalez-Mandly, C Diez, VA Magnotta, NC Andreasen and JL Vazquez-Barquero (2007) Reduced thalamic volume in first-episode non-affective psychosis: Correlations with clinical variables, symptomatology and cognitive functioning. NeuroImage 35, 1613-1623.
68. Cuesta MJ and V Peralta (1995) Cognitive disorders in the positive, negative and disorganization syndromes of schizophrenia. Psychiatr. Res. 58, 227-235.
69. D'Souza DC, E Perry, L MacDougall, Y Ammerman, T Cooper, Y Wu, G Braley, R Gueorguieva, JH Krystal et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahy-drocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. 29, 1558-1572.
70. Daniel DG, DR Weinberger, DW Jones, JR Zigun, R Coppola, S Handel, LB Bigelow, TE Goldberg, KF Berman and JE Kleinman (1991) The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 11, 1907-1917.
71. David AS, A Malmberg, L Brandt, P Allebeck and G Lewis (1997) IQ and risk for schizophrenia: A population-based cohort study. Psychol. Med. 27, 1311-1323.
72. David AS, S Zammit, G Lewis, C Dalman and P Allebeck (2008) Impairments in cognition across the spectrum of psychiatric disorders: Evidence from a Swedish Conscript Cohort. Schizophr. Bull. 2008 Apr 25. [Epub ahead of print].
73. Davis BA, S Shrikhande, VP Paralikar, SR Hirsch, DA Durden and AA Boulton (1991) Phenylacetic acid in CSF and serum in Indian schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 15, 41-47.
74. Dazzan P, KD Morgan, KG Orr, G Hutchinson, X Chitnis, J Suckling et al. (2004) The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain 127, 143-153.
75. DeBoer T, Z Wu, A Lee and TJ Simon (2007) Hippocampal volume reduction in children with chromosome 22q11.2 deletion is associated with cognitive impairment. BioMed. Central 3, 54.
76. Di Forti M, JM Lappin and RM Murray (2007a) Risk factors for schizophrenia--all roads lead to dopamine. Eur. Neuropsychopharmacol. 17 Suppl. 2, S101-S107.
77. Di Forti M, DP Morrison, A Butt and RM Murray (2007b) Cannabis use and psychiatric and cognitive disorders: The chicken or the egg? Curr. Opin. Psychiatry 20, 228-234.
78. Done DJ, TJ Crow, EC Johnstone and A Sacker (1994) Childhood antecedents of schizophrenia and affective illness: Social adjustment at ages 7 and 11. Br. Med. J. 309, 699-703.
79. 1β --Adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J. Neurosci. 22, 2873-2884.
80. Eastvold AD, RK Heaton and KS Cadenhead (2007) Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr. Res. 93, 266-277.
81. Eastwood SL and PJ Harrison (2003) Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. Mol. Psychiatry 8, 821-831.
82. Eliez S, JE Schmitt, CD White and AL Reiss (2000) Children and adolescents with Velocardiofacial syndrome: A volumetric study. Am. J. Psychiatry 157, 409-415.
83. Ettinger U, XA Chitnis, V Kumari, DG Fannon, AL Sumich, SO O'Ceallaigh et al. (2001) Magnetic resonance of the thalamus in first-episode psychosis. Am. J. Psychiatry 158, 116-118.
84. Fallon JH, IO Opole and SG Potkin (2003) The neuroanatomy of schizophrenia: Circuitry and neurotransmitter systems. Clin. Neurosci. Res. 77, 77-107.
85. Feinstein C, S Eliez, C Blasey and AL Reiss (2002) Psychiatric disorders and behavioural problems in children with velocardiofacial syndrome: usefulness as phenotypic indicators of schizophrenia risk. Biol. Psychiatry 51, 312-318.
86. Ferguson DM, IJ Horwood and EM Ridder (2005) Tests of causal linkages between cannabis use and psychotic symptoms. Addict. 100, 354-366.
87. Foong J, MR Symms, GJ Barker, M Maier, DH Miller and MA Ron (2002) Investigating regional white matter in schizophrenia using diffusion tensor imaging. NeuroReport 13, 333-336.
88. Fox MD, AZ Snyder, JL Vincent, M Corbetta, DC Van Essen and ME Raichle (2005) The human brain is intrinsically organised into dynamic, anticorrelated functional networks. Proc. Natl. Acad. Sci. USA 102, 9673-9678.
89. Francey SM, HJ Jackson, LJ Phillips, SJ Wood, AR Yung and PD McGorry (2005) Sustained in young people at high risk of psychosis does not predict transition to psychosis. Schizophr. Res. 79, 127-136.
90. Friston KJ (1998) The disconnection hypothesis. Schizophr. Res. 30, 115-125.
91. Fusar-Poli P, MR Broome, P Matthiasson, SCR Williams, M Brammer and PK McGuire (2007) Effects of acute antipsychotic treatment on brain activation in first episode psychosis: An fMRI study. Eur. Neuropsychopharmacol. 17, 492-500.
92. Gainetdinov RR, WC Wetsel, SR Jones, ED Levin, M Jaber and MG Caron (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283, 397-401.
93. Gerdes M, CB Solot, PP Wang, EM Moss, D LaRossa, P Randall, E Goldmuntz, BJ Clark, DA Driscoll et al. (1999) Cognitive and behavioural profile of preschool children with chromosome 22q11.2 deletion. Am. J. Med. Genet. 85, 127-133.
94. Giancola PR, CS Martin, RE Tarter, WE Pelham and HB Moss (1996) Executive cognitive functioning and aggressive behavior in preadolescent boys at high risk for substance abuse/dependence. J. Stud. Alcohol 57, 352-359.
95. Gilbert AR, DR Rosenberg, K Harenski, S Spencer, JA Sweeney and MS Keshaven (2001) Thalamic volumes in patients with first-episode schizophrenia. Am. J. Psychiatry 158, 618-624.
96. Glashghaei HAT, J Weber, L Pevny, R Schmid, MH Schwab, KC Lloyd et al. (2006) The role of neuregulin-ErbB4 interactions on the proliferation and organisation of cells in the subventricula zone. Proc. Natl. Acad. Sci. USA 103, 1930-1935.
97. Gold JM, C Randolph, CJ Carpenter, TE Goldberg and DR Weinberger (1992) Forms of memory failure in schizophrenia. J. Abnorm. Psychol. 101, 487-494.
98. Gold JM, Carpenter C, C Randolph, TE Goldberg and DR Weinberger (1997) Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch. Gen. Psychiatry 54, 159-165.
99. 1 receptors inprefrontal cells and circuits. Brain Res. Rev. 31, 295-301.
100. 1 receptor mRNA levels: Absence of other neurochemical associations with the enhanced behavioural responses of lesioned rats. J. Neurochem. 63, 1282-1290.
101. Gonzalez-Blanch C, M Alvarez-Jimenez, JM Rodriguez-Sanchez, R Perez-Iglesias, JL Vazquez-Barquero and B Crespo-Facorro (2006) Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: Timing and patterns. Eur. Arch. Psychiatry Clin. Neurosci. 256, 364-371.
102. Gothelf D, G Presburger, AH Zohar, M Burg, A Nahmani, M Frydman, M Shohat, D Inbar, A Aviram-Goldring, J Yeshaya, T Steinberg, Y Finkelstein, A Frisch, A Weizman and A Apter (2004) Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 126, 99-105.
103. Gothelf D, S Eliez, T Thompson, C Hinard, L Penniman, C Feinstein, H Kwon, S Jin, B Jo, SE Antonarakis, MA Morris and AL Reiss (2005) COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat. Neurosci. 8, 1500-1502.
104. Grace AA, SB Floresco, Y Goto and DJ Lodge (2007) Regulation of firing of dopaminergic neurons and control of goal-directed behaviours. Trends Neurosci. 30, 220-227.
105. Grech A, J Van Os, PB Jones, SW Lewis and RM Murray (2005) Cannabis use and outcome of recent onset psychosis. Eur. Psychiatry 20, 223-232.
106. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153, 321-330.
107. Gschwandtner U, J Aston, S Borgwardt, M Drewe et al. (2003) Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: Pre liminary results from the Basel early detection of psychosis study - Fruherkennung von Psychosen (FEPSY). Acta Psychiatr. Scand. 108, 152-155.
108. Gur RE, V Maany, PD Mozley, C Swanson, W Bilker and RC Gur (1998) Subcortical MRI volumes in neuroleptic-naïve and treated patients with schizophrenia. Am. J. Psychiatry 155, 1711-1717.
109. Häfner H and W Van der Heiden (1999) The course of schizophrenia in the light of modern follow-up studies: The ABC and WHO studies. Eur. Arch. Psychiatr. Clin. Neurosci. 249 (Suppl. 4) 14-26.
110. Hahn CG, HY Wang, DS Cho, K Talbot, RE Gur, WH Berrettini et al. (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 12, 824-828.
111. Hambrecht M, M Lammertink, J Klosterkotter, E Matuschek and R Pukrop (2002) Subjective and objective neuropsychological abnormalities in a psychosis prodromal clinic. Br. J. Psychiatry (Suppl.) 43, 30-37.
112. Haroun N, L Dunn, A Haroun and KS Cadenhead (2006) Risk and protection in prodromal schizophrenia: Ethical implications for clinical practice and future research. Schizophr. Bull. 32, 166-178.
113. Harrison PJ and DR Weinberger (2005) Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol. Psychiatry 10, 40-68.
114. Hawkins KA, J Addington, RS Keefe, B Christensen, DO Perkins, R Zipursky et al. (2004) Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr. Res. 67, 115-122.
115. Hay BN (2007) Deletion 22q11: Spectrum of associated disorders. Semin. Pediatr. Neurol. 14, 135-139.
116. Heinrichs RW and KK Zakzanis (1998) Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychol. 12, 426-445. 426-445.
117. Helldin L, JM Kane, U Karilampi, T Norlander and T Archer (2006) Remission and cognitive ability in a cohort of patients with schizophrenia. J. Psychiatr. Res. 40, 738-745.
118. Hellström P, M Edsbagge, T Archer, M Tisell, M Tullberg and C Wikkelsö (2008) The neuropsychology of clinically diagnosed idiopathic normal pressure hydroencephalus. Neurosurgery 61 (6), 1219-1226; discussion 1227-1228.
119. Henquet C, R Murray, D Linszen and J Van Os (2005) The environment and schizophrenia: The role of cannabis use. Schizophr. Bull. 31, 608-612.
120. Heydenbrand G, M Weiser, J Rabinowitz, AL Hoff, LE DeLisi and JG Csernansky (2004) Correlates of cognitive deficits in first episode schizophrenia. Schizophr. Res. 68, 1-9.
121. Hill K, L Mann, KR Laws, CM Stephenson, I Nimmo-Smith and PJ McKenna (2004) Hypofrontality in schizophrenia: A meta-analysis of functional imaging studies. Acta Psychiatr. Scand. 110, 243-256.
122. Hill SK, MSH Harris, ES Herbener, M Pavuluri and JA Sweeney (2008) Neurocognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr. Bull. 34 (4), 743-759. Epub 2008 Apr 29.
123. 1 receptors in twins discordant for schizophrenia. Am. J. Psychiatry 163, 1747-1753.
124. Ho BC, D Alicata, J Ward, DJ Moser, DS O'Leary, S Arndt and NC Andreasen (2003) Untreated initial psychosis: Relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am. J. Psychiatry 160, 142-148.
125. Ho BC, D Alicata, C Mola and NC Andreasen (2005) Hippocampus volume and treatment delays in first-episode schizophrenia. Am. J. Psychiatry 162, 1527-1529.
126. Hoff AL, C Svetina, G Shields, J Stewart and LE DeLisis (2005) Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr. Res. 78, 27-34.
127. Hollis C (2000) Adult outcomes of child- and adolescent-onset schizophrenia: Diagnostic stability and predictive validity. Am. J. Psychiatry 157, 1652-1659.
128. Honea R, TJ Crow, D Passingham and CE Mackay (2005) Regional deficits in brain volume in schizophrenia: A metaanalysis of voxel-based morphometry studies. Am. J. Psychiatry 162, 2233-2245.
129. Honey GD, ET Bullmore, W Soni, M Varatheesan, SC Williams and T Sharma (1999) Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc. Natl. Acad. Sci. USA 96, 13432-13437.
130. Hoogendoorn MLC, JAS Vorstman, GR Jalali, JP Selten, RJ Sinke, BS Emanuel and RS Kahn (2008) Prevalence of 22q11.2 deletions in Dutch patients with schizophrenia. Schizophr. Res. 98, 84-88.
131. Jakob H and H Beckmann (1986) Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J. Neural Transm. 65, 303-326.
132. Jansen PW, SN Duijff, FA Beemer, JAS Vorstman, PWJ Klaasen, MEJ Morcus and JAH Boer (2007) Behavioural problems in relation to intelligence in children with 22q11.2 deletion syndrome: A marched control study. Am. J. Med. Genet. 143, 574-580.
133. Jansma JM, NF Ramsey, R Coppola and RS Kahn (2000) Specific versus nonspecific brain activity in a parametric N-back task. NeuroImage 12, 688-697.
134. Jardin H and AL von Knorring (2003) Diagnostic stability in adolescent onset psychotic disorders. Eur. Child. Adolesc. Psychiatry 12, 15-22.
135. Jayakumar PN, G Venkatasubramamian, BN Gangadhar, N Janakiramaiah and MS Keshavan (2005) Optimized voxelbased morphometry of gray matter volume in first-episode, antipsychotic-naïve schizophrenia. ProgNeuropsychopharmacolBiol. Psychiatry 29, 587-591.
136. Jentsch JD, DE Redmond, JD Elsworth, JR Taylor, KD Youngren and RH Roth (1997) Enduring cortical deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277, 953-955.
137. Johns LC, M Cannon, N Singleton, RM Murray, M Farrell, T Brugha, P Bebbington, R Jenkins and H Meltzer (2004) Prevalance and correlates of self-reported psychotic symptoms in the British population. Br. J. Psychiatry 185, 298-305.
138. Jones SR, RR Gainetdinov, M Jaber, B Giros, RM Wightman and MG Caron (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. USA 95, 4029-4034.
139. Kapadia RK and AS Bassett (2008) Recognizing a common genetic syndrome: 22q11.2 deletion. CMAJ 178, 391-393
140. Kapur S (2003) Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160, 13-23.
141. Karilampi U, L Helldin, F Hjärthag, T Norlander and T Archer (2007) Verbal learning in schizopsychotic outpatients and healthy volunteers as a function of cognitive performance levels. Arch. Clin. Neuropsychol. 22, 161-174.
142. Kates WR, CP Burnette, EW Jabs, J Rutberg, AM Murphy, M Grados, M Geraghty, WE Kaufmann and GD Pearlson (2001) Regional cortical white matter reductions in velocardiofacial syndrome: A volumatric MRI analysis. Biol. Psychiatry 49, 677-684.
143. Kawasaki Y, M Suzuki, S Nohara, H Hagino, T Takahashi, M Matsui, I Yamashita, XA Chitnis, PK McGuire, H Seto and M Kurachi (2004) Structural brain differences in patients with schizophrenia and schizotypal disorder demonstrated by voxel-based morphometry. Eur. Arch. Psychiatr. Clin. Neurosci. 254, 406-414.
144. Keefe RS, SE Lees-Roitman and RL Dupre (1997) Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. Schizophr. Res. 26, 9-14.
145. Keefe RS, DO Perkins, H Gu, RB Zipursky, BK Christensen and JA Lieberman (2006) A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr. Res. 88, 26-35.
146. 2O PET study. Am. J. Psychiatry 160, 919-923.
147. Klosterkotter J, M Hellmich, EM Steinmeyer and F Schultze Lutter (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry 58, 158-164.
148. 2 receptor antagonism. J. Neurosci. 26, 4236-4246.
149. Konick LC and L Friedman (2001) Meta-analysis of thalamic size in schizophrenia. Biol. Psychiatry 49, 28-38.
150. Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19, 1-17.
151. Kostrzewa RM and R Brus (1991) Ontogenetic homologous supersensitization of quinpirole-induced yawning in rats. Pharmacol. Biochem. Behav. 39, 517-519.
152. 2 receptors. Eur. J. Pharmacol. 183, 1411-1412.
153. Kostrzewa RM, NY Huang, JP Kostrzewa, P Nowak and R Brus (2007) Modeling tardive dyskinesia: Predictive 5-HT2C receptor antagonist treatment. Neurotox. Res. 11, 41-50.
154. Kostrzewa RM, JP Kostrzewa, RW Brown, P Nowak and R Brus (2008) Dopamine receptor supersensitivity: Development, mechanisms, presentation, and clinical applicability. Neurotox. Res. 14, 121-128.
155. Kovoor A, P Seyffarth, J Ebert, S Barghshoon, CK Chen, S Schwarz, JD Axelrod, BN Cheyette, MI Simon, HA Lester and J Schwarz (2005) D 2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J. Neurosci. 25, 2157-2165.
156. Krug A, V Markov, D Leube, K Zerres, T Eggermann, MM Nöthen, MH Skowronek, M Rietschel and T Kircher (2008) Genetic variation in the schizophrenia-risk gene neureglin1 correlates with personality traits in healthy individuals. Eur. Psychiatry 23 (5), 344-349. Epub 2008 May 1.
157. Kurachi M (2003) Pathogenesis of schizophrenia: Part II. Tempero-frontal two-step hypothesis. Psychiatr. Clin. Neurosci. 57, 9-15.
158. Laakso A, H Vilkman, D Alakare, M Haaparanta, J Bergman, O Solin, J Peurasaari, V Rakkolainen, E Syvalahti and J Hietala (2000) Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am. J. Psychiatry 157, 269-271.
159. Lang DJ, B Khorram, VM Goghari, LC Kopala, RA Vandorpe, Q Rui et al. (2006) Reduced anterior internal capsule and thalamic volumes in first episode psychosis. Schizophr. Res. 87, 89-99.
160. Laruelle M (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res. Brain Res. Rev. 31, 371-384.
161. Laruelle M and A Abi-Dargham (1999) Dopamine as the wind of psychotic fire: New evidence from brain imaging studies. J. Psychopharmacol. 13, 358-371.
162. Laurent A, D Duly, P Murry, N Foussard, S Boccara, F Mingat, J Dalery and T d'Amato (2001) WCST performance and schizotypal features in the first-degree relatives of patients with schizophrenia. Psychiatr. Res. 104, 133-144.
163. Lawrie SM, HC Whalley, SS Abukmeil, JN Kestelman, L Donnelly, P Miller et al. (2001) Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol. Psychiatry 49, 811-823.
164. Lencz T, CW Smith, D McLaughlin, A Auther, E Nakayama, L Hovey and BA Cornblatt (2006) Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatry 59, 863-871.
165. Lewis DA and P Levitt (2002) Schizophrenia as a disorder of neurodevelopment. Ann. Rev. Neurosci. 25, 409-432.
166. Li D, DA Collier and L He (2006) Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum. Mol. Genet. 15, 1995-2002.
167. Liang M, Y Zhou, T Jiang, Z Liu, L Tian, H Liu and Y Hao (2006) Widespread functional disconnectivity in schizophrenia with resting state functional magnetic resonance imaging. NeuroReport 17, 209-213.
168. Lisman JE, JT Coyle, RW Green, DC Javitt, FM Benes, S Heckers and AA Grace (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. TINS 31, 234-242.
169. Lodge DJ and AA Grace (2006) The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacol. 31, 1356-1361.
170. Lodge DJ and AA Grace (2007) Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J. Neurosci. 27 (42), 11424-11430.
171. Lodge DJ and AA Grace (2008) Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotox. Res. 14 (97-104).
172. Lucas LR, Z Celen, KL Tamashiro, RJ Blanchard, DC Blanchard, C Markham, RR Sakai and BS McEwen (2004) Repeated exposure to social stress has long-term effects on indirect markers of dopaminergic activity in brain regions associated with motivated behavior. Neuroscience 124, 449-457.
173. Luzi S, PD Morrison, J Powell, M Di Forti and RM Murray RM (2008) What is the mechanism whereby cannabis use increases risk of psychosis? Neurotox. Res. 14 (105-112).
174. Malaspina D, J Harkavy-Friedman, C Corcoran, L Mujica-Parodi, D Printz, JM Gorman and R Van Heertum (2004) Resting neural activity distinguishes subgroups of schizophrenia patients. Biol. Psychiatry 56, 931-937.
175. Malmberg A, G Lewis, AS David and P Allebeck (1998) Premorbid adjustment and personality in schizophrenia. Br. J. Psychiatry 172, 308-313.
176. Manoach DS, RL Gollub, ES Benson, MM Searl, DC Goff, E Halpern, CB Saper and SL Rauch (2000) Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol. Psychiatry 48, 99-109.
177. Marneros A, A Deister and A Rohde (1991) Stability of diagnosis in affective, schizoaffective and schizophrenic disorders. Cross-sectional versus longitudinal diagnosis. Eur. Arch. Psychiatr. Clin. Neurosci. 241, 187-192.
178. Matsui M. H Yuuki, K Kato and M Kurachi (2006) Impairment of memory organisation in patients with schizophrenia or schizotypal disorder. J. Int. Neuropsychol. Soc. 12, 750-754.
179. McGlashan TH (2001) Psychosis treatment prior to psychosis onset: ethical issues. Schizophr. Res. 51, 47-54.
180. McGlashan TH, RB Zipursky, D Perkins, J Addington, T Miller, SW Woods et al. (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 163, 790-799.
181. McGorry PD, A Yung and L Phillips (2001) Ethics and early intervention in psychosis: Keeping up the pace and staying in step. Schizophr. Res. 51, 17-29.
182. 18 F]fluorodopa study. Arch. Gen. Psychiatry 61, 134-142.
183. McQueen MB, B Devlin, SV Faraone, VL Nimgaonkar, P Sklar, JW Smoller, R Abou Jamra, M Albus, SA Bacanu et al. (2005) Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosome 6q and 8q. Am. J. Hum. Genet. 77, 582-595.
184. Meyer-Lindenberg AS, RK Olsen, PD Kohn, T Brown, MF Egan, DR Weinberger and KF Berman (2005) Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch. Gen. Psychiatry 62, 379-386.
185. Michaelovsky E, D Gotelf, M Korostishevsky, A Frisch, M Burg, M Carmel, T Steinberg, D Inber, A Apter and A Weizman (2007) Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int. J. Neuropsychopharmacol. 11 (3), 351-363. Epub 2007 Oct 22.
186. Miller YJ, TH McGlashan, JL Rosen, K Cadenhead, T Cannon, J Ventura et al. (2003) Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptomes: Predictive validity, interrater reliability, and training for reliability. Schizophr. Bull. 29, 703-715.
187. Mohammed AK, G Jonsson, U Söderberg and T Archer (1986a) Impaired selective attention in methylazoxymethanol-induced microencephalic rats. Pharmacol. Biochem. Behav. 24, 975-981.
188. Mohammed AK, G Jonsson, E Sundström, BG Minor, U Söderberg and T Archer (1986b) Selective attention and place navigation in rats treated prenatally with methyl-azoxymethanol. Dev. Brain Res. 30, 145-155.
189. Moore H, JD Jentsch, M Ghajarnia, MA Geyer and AA Grace (2006) A neurobehavioural systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: Implications for the neuropathology of schizophrenia. Biol. Psychiatry 60, 253-264.
190. Morrison AP, P French, L Walford, SW Lewis, A Kilcommons, J Green et al. (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: Randomised control trial. Br. J. Psychiatry 185, 291-297.
191. Mortensen EL, HJ Sorensen, HH Jensen, JM Reinisch and SA Mednick (2005) IQ and mental disorder in young men. Br. J. Psychiatry 187, 407-415.
192. Mirnics K, FA Middleton, DA Lewis and P Levitt (2001) The human genome: gene expression profiling and schizophrenia. Am. J. Psychiatry 158, 1384.
193. Murphy BL, AFT Arnsten, PS Goldman-Rakic and RH Roth (1996) Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Neurobiol. 93, 1325-1329.
194. Murphy KC and PJ Scambler (2005) Velo-cardio-facial Syndrome: A Model for Understanding Microdeletion Disorders (Cambridge University Press:CAmbridge).
195. Murphy KC, LA Jones and MJ Owen (1999) High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry 56, 940-945.
196. Murray RM, Jones P, O'Callaghan E, Takei N and Sham P (1992) Genes, viruses and neurodevelopmental schizophrenia. J. Psychiatr. Res. 26, 225-235.
197. Murray RM, DP Morrison, C Henquet and M Di Forte (2007) Cannabis, the mind and society: The harsh realities. Nat. Rev. Neurosci. 8, 885-895.
198. Nakamura M, PG Nestor, JJ Levitt, AS Cohen, T Kawashima, ME Shenton and RW McCarley (2008) Orbitofrontal volume deficit in schizophrenia and thought disorder. Brain 131, 180-195.
199. Narendran R, WG Frankle, R Keefe, R Gil, D Martinez, M Slifstein, LS Kegeles, PS Talbot, Y Huang, DR Hwang, L Khenissi, TB Cooper, M Laruelle and A Abi-Dargham (2005) Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am. J. Psychiatry 162, 2352-2359.
200. Nave KA and JL Salzer (2006) Axonal regulation of myelination by neuregulin 1. Curr. Opin. Neurobiol. 16, 492-500.
201. Niendam TA, J Horwitz, CE Bearden and TD Cannon (2007) Ecological assessment of executive dysfunction in the psychosis prodrome: A pilot study. Schizophr. Res. 93, 350-354.
202. Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 67, 53-83. Review.
203. Niklasson L, P Rasmussen, S Oskarsdottir and C Gillberg (2001) Neuropsychiatric disorders in the 22q11 deletion syndrome. Genet. Med. 3, 79-84.
204. Numata S, SI Ueno, JI Iga, H Song, M Nakatagi, S Tayoshi, S Sumitani, M Tomotaki, M Itakura, A Sano and T Ohmori (2008) Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in a Japanese population. J. Psychiatr. Res. 2008 Mar 7. [Epub ahead of print].
205. O'Driscoll GA, MF Lenzenweger and PS Holzman (1998) Anti-saccades and smooth pursuit eye tracking and schizotypy. Arch. Gen. Psychiatry 55, 837-843.
206. Öie M and BR Ruud (1999) Neuropsychological deficits in adolescent-onset schizophrenia compared with attention deficit hyperactivity disorder. Am. J. Psychiatry 156, 1216-1222.
207. Palomo T, T Archer, RM Kostrzewa and RJ Beninger (2004) Gene-environment interplay in schizopsychotic disorders. Neurotox. Res. 6, 1-10.
208. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (2008) Focusing on symptoms rather than diagnoses in brain dys-function: Conscious and nonconscious expressions in impulsiveness and decision-making. Neurotox. Res. 14, 1-20.
209. Papalos DF, GL Faedda, S Veit, R Goldberg, B Morrow, R Kucherlapati and RJ Shprintzen (1996) Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: Does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder. Am. J. Psychiatry 153, 1541-1547.
210. Park S (1997) Association with an oculomotor delayed response task and the Wisconsin Card Sort Test in schizophrenic patients. Int. J. Psychophysiol. 27, 147-151.
211. Pearlson GD and BS Folley (2008) Endophenotypes, dimensions, risks: Is psychosis analogous to common inherited medical illnesses? Clin. EEG Neurosci. 39, 73-77.
212. Penschuck S, P Flagstad, M Didriksen, M Leist and AT Michael-Titus (2006) Decrease in paralbumin-expressing neurons in the hippocampus and increased phencyclidineinduced locomotor activity in the rat methylazoxymetnanol (MAM) model of schizophrenia. Eur. J. Neurosci. 23, 279-284.
213. Pickard BS, MP Malloy, DJ Porteous, DH Blackwood and WJ Muir (2005) Disruption of a brain transcription factor, NPAS3, is associated with schizophrenia and learning disability. Am. J. Med. Genet. B Neuropsychiatr. Genet. 136, 26-32.
214. Pickard BS, MP Malloy, A Christoforou, PA Thomson, KL Evans, S WMorris, M Hampson, DJ Porteous, DH Blackwood and WJ Muir (2006) Cytogenetic and genetic evidence support a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol. Psychiatry 11, 847-857.
215. Pickard BS, PA Thomson, A Christoforou, KL Evans, SW Morris, DJ Porteous, DH Blackwood and WJ Muir (2007) The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatr. Genet. 17, 129-133.
216. Pickard BS, A Christoforou, PA Thomson, A Fawkes, KL Evans, SW Morris, DJ Porteous, DH Blackwood and WJ Muir (2008) Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Mol. Psychiatry 2008 Mar 4. [Epub ahead of print].
217. Poon E, DA Ellis, HE Fitzgerald and RA Zucker (2000) Intellectual, cognitive and academic performance among sons of alcoholics, during the early school years: Differences related to subtypes of fammilial alcoholism. Alcohol Clin. Exp. Res. 24, 1020-1027.
218. Portas CM, JM Goldstein, ME Shenton, HH Hokama, CG Wible et al. (1998) Volumetric evaluation of the thalamus in schizophrenia male patients using magnetic resonance imaging. Biol. Psychiatry 43, 649-659.
219. Preuss UW, T Zetzsche, M Jäger, C Groll, T Frodl, R Bottlender et al. (2005) Thalamic volume in first-episode and chronic schizophrenic subjects: A volumetric MRI study. Schizophr. Res. 73, 91-101.
220. Raichle ME and MA Mintun (2006) Brain work and brain imaging. Ann. Rev. Neurosci. 29, 449-476.
221. Rodríguez-Sánchez JM, R Pérez-Iglesias, C González-Blanch, JM Pelayo-Terán, I Mata, O Martínez, I Sánchez-Cubillo, JL Vázquez-Barquero and B Crespo-Facorro (2008) 1-year follow-up study of cognitive function in first-episode non-affective psychosis. Schizophr. Res. 104 (1-3), 165-174.
222. Romney DM (1987) A simplex model of the paranoid process: Implications for diagnosis and prognosis. Acta Psychiatr. Scand. 75, 651-655.
223. Ross CA, RL Margolis, SA Reading, M Pletnikov and JT Coyle (2006) Neurobiology of schizophrenia. Neuron 52, 139-153.
224. Roth RH, SY Tam, Y Ida, JX Yang and AY Deutch (1988) Stress and the mesocorticolimbic systems. Ann. NY Acad. Sci. 537, 138-147.
225. Ruud BR (1998) A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr. Bull. 24, 425-435.
226. Ruud BR, I Melle, S Friis, TK Larsen, LJ Midböe, S Opjordsmoen, E Simonsen, P Vaglum and T McGlashan (2004) Neurocognitive dysfunction in first-episode psychosis: Correlates with symptoms, premorbid adjustment and duration of untreated psychosis. Am. J. Psychiatry 161, 466-472.
227. Ruud BR, I Melle, S Friis, JO Johannessen, TK Larsen, LJ Midböe, S Opjordsmoen, E Simonsen, P Vaglum and T McGlashan (2007) The course of neurocognitive functioning in first-episode psychosis and iys relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr. Res. 91, 132-140.
228. Salomon L, C Lanteri, J Glowinski and JP Tassin (2006) Behavioural sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. Proc. Natl. Acad. Sci. USA 103, 7476-7481.
229. Saykin AJ, RC Gur, RE Gur, PD Mozley, LH Mozley, SM Resnick, DB Kesterand, P Stainiak (1991) Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Arch. Gen. Psychiatry 48, 618-624.
230. Schlosser R, T Gesierich, B Kaufmann, G Vucurevic, S Hunsche, J Gawhn and P Stoeter (2003) Altered effective connectivity during working memory performance in schizophrenia: A study with fMRI and structural equation modeling. NeuroImage 19, 751-763.
231. Schwab SG, M Knapp, S Mondabon, J Hallmayer, M Borrmann-Hassenbach, M Albus et al. (2003) Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 72, 185-190.
232. Scully PJ, G Coakley, A Kinsella and JL Waddington (1997) Psychopathology, executive function and general cognitive impairment in relation to duration of initially untreated versus subsequent treated psychosis in chronic schizophrenia. Psychol. Med. 27, 1303-1310.
233. Seeman P, T Tallerico, F Ko, C Tenn and S Kapur (2002) Amphetamine-sensitized animals show marked increase in dopamine D 2 High receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46 235-239.
234. 2 High states, implying many parhways to psychosis. Proc. Natl. Acad. Sci. USA 102, 3513-3518.
235. 2 High dopamine receptors. Synapse 60, 319-346.
236. 2 High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61, 573-576.
237. Seeman P, F Ko, E Jack, R Greenstein and B Dean (2007b) Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 61, 303-309.
238. Segurado R, SD Detera-Wadleigh, DF Levinson, CM Lewis, M Gill, JI Nurnberger, N Craddock, JR DePaulo, M Baron et al. (2003) Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am. J. Hum. Genet. 73, 49-62.
239. Shprintzen RJ (2000) Velo-cardio-facial syndrome: A distinction behavioral phenotype. Ment. Retard. Dev. Disabil. Res. Rev. 6, 142-147.
240. Siever LJ and KL Davis (2004) The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. Am. J. Psychiatry 161, 398-413.
241. Simon TJ, JP Bish, CE Bearden, L Ding, S Ferrante, V Nguyen, JC Gee, DM McDonald-McGinn, EH Zackai and BS Emannuel (2005) A multiple levels analysis of cognitive dysfunction and psychopathology associated with chromosome 22q11.2 deletion syndrome in children. Dev. Psychopathol. 17, 753-784.
242. Smit F, L Bolier and P Cuijpers (2004) Cannabis use and the risk of later schizophrenia: A review. Addict. 99, 425-430.
243. Sora I, FS Hall, AM Andrews, M Itokawa, XF Li, HB Wei, C Wichems, KP Lesch, DL Murphy and GR Uhl (2001) Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA 98, 5300-5305.
244. Spence SA, PF Liddle, MD Stefan, JS Hellewell, T Sharma, KJ Friston, SR Hirsch, CD Frith, RM Murray, JF Deakin and PM Grasby (2000) Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk. Focal dysfunction and distributed disconnectivity reappraised. Br. J. Psychiatry 176, 52-60.
245. Staal WG, HE Hulshoff Pol, H Schnack, AC ven der Schot and RS Kahn (1998) Partial volume decrease of the thalamus in relatives of patients with schizophrenia. Am. J. Psychiatry 155, 1784-1786.
246. Stefanis NC, M Hanssen, NK Smirnis et al. (2002) Evidence that three dimensions of psychosis have a distribution in the general population. Psychol. Med. 32, 347-358.
247. Stephan KE, T Baldeweg and KJ Friston (2006) Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 59, 929-939.
248. Stirling J, C White, S Lewis, R Hopkins, D Tantam, A Huddy and L Montague (2003) Neurocognitive function and outcome in first-episode schizophrenia: A 10-year follow-up of an epidemiological cohort. Schizophr. Res. 65, 75-86.
249. Sullivan PF, KS Kendler and MC Neale (2003) Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 60, 1187-1192.
250. Swillen A, L Vandputte, J Cracco, B Maes, P Ghesquiere, K Devriendt and JP Fryns (1999) Neuropsychological, learning and psychosocial profile of primary school aged children with the velo-cardio-facial syndrome (22q11 deletion): Evidence for a nonverbal learning disability? Child. Neuropsychol. 5, 230-241.
251. Talamini LM, T Koch, GJ Ter Horst and J Korf (1998) Methylazoxymetnanol acetate-induced abnormalities in the entorhinal cortex of the rat: parallels with morphological findings in schizophrenia. Brain Res. 789, 293-306.
252. 11 C] FLB. Int. J. Neuropsychopharmacol. 6, 361-370.
253. 1β - adrenoceptor knockout supersensitive mice. Synapse 61, 569-572.
254. Tenn C, PJ Fletcher and S Kapur (2003) Amphetaminesensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr. Res. 64, 103-114.
255. Tenn C, PJ Fletcher and S Kapur (2005) A putative animal model of the "prodromal" state of schizophrenia. Biol. Psychiatry 57, 586-593.
256. Tian L, T Jiang, Y Wang, Y Zang, Y He, M Liang, M Sui, Q Cao, S Hu, M Peng and Y Zhou (2006) Altered resting state functional connectivity patterns of anterior cingulate cortex in adolescents with attention deficit hyperactivity disorder. Neurosci. Lett. 400, 39-43.
257. Townsend LA, RMG Norman, AK Malla, AD Rychlo and RR Ahmed (2002) Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders. Psychiatr. Res. 113, 69-81.
258. Tsuang MT, RF Woolson, G Winokur and RR Crowe (1981) Stability of psychiatric diagnosis. Schizophrenia and affective disordersfollowed up over a 30- to 40-year period. Arch. Gen. Psychiatry 38, 535-539.
259. 1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacol. 30, 1861-1869.
260. Uhl GR, FS Hall and I Sora (2002) Cocaine, reward, movement and monoamine transporters. Mol. Psychiatry 7, 21-26.
261. Van Amelsvoort T, E Daly, D Robertson, J Suckling, V Ng, H Critchley, MJ Owen, J Henry, KC Murphy and DGM Murphy (2001) Structural brain abnormalities associated with the deletion at chromosome 22q11. Br. J. Psychiatry 178, 412-419.
262. Van der Werf YD, P Scheltens, J Lindeboom, MP Witter, HB Uylings and J Jolles (2003) Deficits of memory, executive functioning and attention following infarction of the thalamus: A study of 22 cases with localized lesions. Neuropsychologia 41, 1330-1344.
263. Van Os J, M Bak, M Hanssen, RV Bijl, R de Graaf and H Verdoux (2002) Cannabis use and psychosis: A longitudinal population-based study. Am. J. Epidemiol. 156, 319-327.
264. Wang EW, R Rogers, CL Giles, PM Diamond, LE Herrington-Wang and ER Taylor (1997) Apilot study of the Personality Assessment Inventory (PAI) in corrections: Assessment of malingering, suicide risk, and aggression in male inmates. Behav. Sci. Law 15 (4), 469-482.
265. Wang L, Y Zang, Y He, M Liang, X Zhang, L Tian, T Wu, T Jiang and K Li (2006) Changes in hippocampal connectivity in the early stages of Alzheimer's disease: Evidence from resting state fMRI. NeuroImage 31, 496-504.
266. Weinberger DR and RK McClure (2002) Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: What is happening in the schizophrenic brain? Arch. Gen. Psychiatry 59, 553-558.
267. Williams GV and SA Castner (2006) Under the curve: Critical issues for elucidating D 1 receptor function in working memory. Neuroscience 139, 263-276.
268. Wyatt RJ, LM Damiani and ID Henter (1998) First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. Br. J. Psychiatry 172, 77-83.
269. Xu F, RR Gainetdinov, WC Wetsel, SR Jones, LM Bohn, GW Miller, YM Wang and MG Caron (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat. Neurosci. 3, 465-471.
270. Yung AR and PD McGorry (1996) The prodromal phase of first-episode psychosis: Past and current conceptualizations (review). Schizophr. Bull. 22, 253-270.
271. Yung AR, LJ Phillips, HP Yuen, SM Francey, CA MacFarlane, M Hallgren et al. (2003) Psychosis prediction: 12-month follow-up of a high-risk ("prodromal") group. Schizophr. Res. 60, 21-32.
272. Zammit S, P Allebeck, S Andreasson, I Lundberg and G Lewis (2002) Self-reported cannabis use as a risk factor for schizophrenia: Further analysis of the 1969 Swedish conscript cohort. BMJ 325, 1199-1201.
273. Zammit S, P Allebeck, AS David, C Dalman, T Hemmingsson, I Lundberg and G Lewis (2008) A longitudinal study of premorbid IQ score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch. Gen. Psychiatry 61, 354-360.
274. Zhang LI and MM Poo (2001) Electrical activity and development of neural circuits. Nat. Neurosci. 4 (Suppl.), 1207-1214.
275. Zhou Y, M Liang, T Jiang, L Tian, Y Liu, Z Liu, H Liu and F Kuang (2007) Functional dysconnectivity of the dorsolateral prefrontal cortex in first-episode schizophrenia using resting-state fMRI. Neurosci. Lett. 417, 297-302.